Renovo plc

Renovo Group plc was a biopharmaceutical company, which was founded in 1998 and was headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate Juvista, all 100 of Renovo's staff were laid off in 2011.[2][3][4]

Renovo Group plc
TypePublic limited company
IndustryBiotechnology
FoundedOctober 2000
DefunctMay 2011 (2011-05)
Headquarters
Manchester
,
United Kingdom
Key people
Mark Ferguson (CEO)
Number of employees
110
WebsiteArchived 24 July 2013 at the Wayback Machine

Although the company stopped all pharmaceutical development it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.[5][6]

Products

Renovo does not currently have any marketed products. Its development pipeline currently includes one drug in phase III clinical development, two drugs in phase II clinical development, and numerous pre-clinical candidates.[7]

Drug Phase Action
Juvista Failed[8] Injected to the wound margins around the time of surgery causes a prevention or reduction of scarring through introduction of recombinant TGFβ3.
Adaprev Halted[9] Injected at the time of surgery for the prevention and reduction of scarring and adhesions between the tendon and surrounding tissues following tendon repair.].
Prevascar Halted[10] Injected to the wound margins around the time of surgery causes a reduction of scarring through suppression of TGFβ1 and TGFβ2.
Juvidex Renovo planned to partner Juvidex as a cosmetic ingredient for the improvement of skin appearance and to promote the healing of damaged skin.
RN1005 Phase I Clinical trial RN1005 is an advanced preclinical candidate pharmaceutical, discovered by Renovo, targeting the Wnt pathway to reduce scarring and enhance tissue regeneration.

References
  1. London Regenerative Medicine Network – January 2007 Meeting Archived 28 September 2007 at the Wayback Machine
  2. Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012). Manchester Evening News.
  3. Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  4. Grogan, Kevin (31 May 2001). "Future bleak for Renovo with no workers or products". PharmaTimes. Retrieved 14 December 2016.
  5. Rename Plan for Renovo (16 July 2014). InsiderMedia.com
  6. "Company Overview of Inspired Capital plc". Bloomberg. Retrieved 14 December 2016.
  7. Renovo – Products Archived 25 January 2010 at the Wayback Machine
  8. "Pharma Times" Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
  9. Ashcroft, Jamie. (18 November 2011) "ProactiveInvestors" – Renovo ends Adaprev development (18 November 2011). Proactiveinvestors.co.uk.
  10. Ashcroft, Jamie. (16 April 2012) "ProactiveInvestor" Renovo ends Prevascar development (16 April 2012). Proactiveinvestors.co.uk.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.